Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

South Korean scientists have created the first ever truly hypoallergenic cat

The post Meet Alsik: the CRISPR cat you can cuddle  appeared first on Medical News Bulletin.

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Hair transplants are becoming increasingly common, however, that does not mean, the fear of getting them has ebbed in people. It is a serious surgical procedure that requires your time and patience. Also, you need professionals to do the job because a shoddy hair transplant can scar you for life. Therefore, if you are looking […]

The post Questions to Ask Before Choosing a Hair Transplant Clinic appeared first on Medical News Bulletin.

At this year’s San Antonio Breast Cancer Symposium, Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award.
Giuliano will receive the award, which recognizes physicians who have made significant contributions to the field of breast oncology, on the second day of the symposium.
He is being recognized for pioneering sentinel lymph node biopsy technique for breast cancer, a procedure that identifies and removes the lymph nodes where cancer is likely to spread first.
Giuliano led the ACOSOG Z0010 and ACOSOG Z0011 trials, which validated that sentinel node biopsy was a

BOSTON — Optometrists need to know about generational differences in contact lens preferences, according to a speaker here.
While Gen Z patients do not use as many contacts as millennials, “the Gen Zs are more into technologies, so they’re looking more into UV protection and digital device usage,” Roxanne Achong-Coan, OD, FAAO, FIAOMC, FSLS, FBCLA, told Healio at Academy 2025. “It’s all about their life. ... They’re all about their appearance and what looks good for them, so they’re on TikTok, they’re doing the latest styles on everything, and they want to have visual freedom.”
{{VIDEO}}
On the

PARIS — AI is advancing our understanding of the complexities of age-related macular degeneration, according to a presenter.
At the Euretina congress Ursula Schmidt-Erfurth, MD, said AI and AI-based tools are providing guidance on disease management, supporting research and drug development and creating opportunities for community-based eye screening.
Schmidt-Erfurth, who was honored with the Euretina Lecture, reviewed the many applications of AI-based OCT analysis.
In neovascular AMD, AI algorithms can quantify and monitor the changes in fluid volume in three compartments: intraretinal fluid

HOUSTON — In this video, Laura Aponte Becerra, MD, discusses promising results from the MIRO-CKD and the SURPASS-CVOT trials presented at ASN Kidney Week.
“The take-home message across these two studies is that we’re seeing a strong and consistent theme, which are layered kidney protection,” Aponte Becerra, a nephrology fellow at Yale School of Medicine, told Healio. “So, SGLT-2 inhibitors remain foundational, but adding therapies such as balcinrenone (AstraZeneca) or tirzepatide (Mounjaro/Zepbound, Eli Lilly) may meaningfully reduce albuminuria, slow eGFR decline

Several changes in the 2026 Medicare Physicians Fee Schedule, or PFS, will help to better support primary, preventive and comprehensive health care, according to several organizations.
For example, the PFS introduces an efficiency adjustment that ACP said “will help account for how clinical practices and resource utilization patterns evolve and better align payments with those changes.”
The Primary Care Collaborative similarly applauded practice expense reimbursement reform, as well as improvements to the Medicare Diabetes Prevention Program and Advanced Primary Care Management

ORLANDO — The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune thrombocytopenia, according to randomized phase 3 study results.
The combination prolonged time to treatment failure by more than 40% compared with eltrombopag alone, data presented during ASH Annual Meeting and Exposition’s late-breaking abstract session showed. It also increased the likelihood that patients would remain in stable response at 6 months.
The findings suggest the regimen may support longer periods of disease control, which could help alleviate the

ORLANDO — Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a randomized phase 3 trial.
The data, presented at ASH Annual Meeting and Exposition and co-published in Journal of Clinical Oncology, showed pirtobrutinib (Jaypirca, Eli Lilly & Co.) reduced the risk for progression or death 80% compared with bendamustine plus rituximab (Rituxan; Genentech, Biogen).
Combined with data from another trial presented at ASH, which showed promising PFS results

ORLANDO — “The best PFS results we’ve ever seen in relapsed, refractory myeloma.”
The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for disease progression or death 83% from standard daratumumab and dexamethasone with either pomalidomide or bortezomib, according to findings of a randomized phase 3 trial presented at ASH Annual Meeting and Exposition and co-published in The New England Journal of Medicine.
Teclistamab plus daratumumab (Tec-Dara) also significantly improved response as patients who received the therapy